Exoxemis is a biomedical research company
Focused on the study and commercialization of Zempia®, our trade name for topical biological antiseptic system utilizing Myeloperoxidase (MPO).
Exoxemis develops haloperoxidase products for prevention and treatment of serious infections, to address the growing problem of microbial drug resistance.
The myeloperoxidase (MPO) technology is a versatile platform that can be leveraged into multiple product areas, including medical, biodefense, industrial, veterinary, and disinfectant applications.
We are committed to integrating our technology with the intellectual, financial, and commercial strengths of prospective partners to develop innovative products and long-term relationships.